KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Total Debt (2016 - 2025)

Historic Total Debt for Jazz Pharmaceuticals (JAZZ) over the last 17 years, with Q3 2025 value amounting to $5.4 billion.

  • Jazz Pharmaceuticals' Total Debt fell 1228.18% to $5.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.4 billion, marking a year-over-year decrease of 1228.18%. This contributed to the annual value of $6.1 billion for FY2024, which is 692.63% up from last year.
  • Jazz Pharmaceuticals' Total Debt amounted to $5.4 billion in Q3 2025, which was down 1228.18% from $5.4 billion recorded in Q2 2025.
  • Jazz Pharmaceuticals' 5-year Total Debt high stood at $6.7 billion for Q2 2021, and its period low was $2.1 billion during Q1 2021.
  • Moreover, its 5-year median value for Total Debt was $5.7 billion (2023), whereas its average is $5.6 billion.
  • Per our database at Business Quant, Jazz Pharmaceuticals' Total Debt surged by 22038.61% in 2021 and then crashed by 1228.18% in 2025.
  • Jazz Pharmaceuticals' Total Debt (Quarter) stood at $6.0 billion in 2021, then dropped by 5.38% to $5.7 billion in 2022, then dropped by 0.2% to $5.7 billion in 2023, then rose by 6.93% to $6.1 billion in 2024, then fell by 12.24% to $5.4 billion in 2025.
  • Its Total Debt was $5.4 billion in Q3 2025, compared to $5.4 billion in Q2 2025 and $5.4 billion in Q1 2025.